Biography
Thierry M. Jahan, M.D. is a renowned medical oncologist who specializes in the treatment of thoracic malignancies such as lung cancer and mesothelioma, and soft tissue sarcomas. Dr. Jahan received his M.D. from George Washington University, thereafter completing his residency and internal medicine residency at Cedars Sinai Medical Center in Los Angeles. He later was a clinical fellows in hematology and oncology at UCSF, eventually joining the UCSF faculty. Dr. Jahan co-founded the Thoracic Oncology Program with David Jablons, M.D.
In addition to his keen clinical insight, Dr. Jahan is known by patients, their families and fellow clinicians for his sense of empathy and compassion. His steadfast commitment to eliminating the scourge of lung cancer is evidenced by the pins and ribbons adorning his white coat, a clear message of hope to patients.
In 2016, Dr. Jahan was inducted into the Council of Master Clinicians by the UCSF Department of Medicine, a select group of outstanding physicians with exceptional knowledge, superior teaching and communication skills, and the ability to provide compassionate, appropriate, effective, and high-quality patient care.
Dr. Jahan has been the recipient of numerous awards including the Medical House Staff Outstanding Teacher Award and Friend of the Palliative Care Service Award. He is also a member of numerous professional organizations, including the American College of Physicians, American Society of Clinical Oncology (ASCO), and International Association for the Study of Lung Cancer (IASLC) and the Association of Northern California Oncologists.
Dr. Jahan has authored or co-authored numerous peer-reviewed articles, book chapters and research abstracts and lectured nationally and internationally on lung cancer and mesothelioma. Numerous major media outlets including The San Francisco Chronicle, Time Magazine and KPIX San Francisco have sought out his opinions and observations on treatments and advances in lung cancer.
Education
Institution | Degree | Dept or School | End Date |
---|---|---|---|
University of California, San Francisco | Fellowship | Hematology/Oncology | 06/1994 |
University of California, Los Angeles | Kennamer Fellowship | Internal Medicine | 06/1991 |
University of California, Los Angeles | Residency | Internal Medicine | 06/1990 |
George Washington University School of Medicine and Health Sciences | MD | 06/1987 | |
Columbia University | BA | Psychology | 05/1983 |
Clinical Trials
- Related Conditions: Mesothelioma, Lung Cancer, Lung Tumor| Start Date: | End Date:
In the News
Publications
- First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.| | View in PubMed
- Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.| | View in PubMed
- Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.| | View in PubMed
- Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.| | View in PubMed
- Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.| | View in PubMed
- Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.| | View in PubMed
- Distinct attentional function profiles in older adults receiving cancer chemotherapy.| | View in PubMed
- Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.| | View in PubMed
- Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer.| | View in PubMed
- Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.| | View in PubMed
- NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.| | View in PubMed
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.| | View in PubMed
- Intraoperative Radiotherapy in the Management of Locally Recurrent Extremity Soft Tissue Sarcoma.| | View in PubMed
- Non-Small Cell Lung Cancer, Version 6.2015.| | View in PubMed
- Non-small cell lung cancer, version 1.2015.| | View in PubMed
- A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer.| | View in PubMed
- Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.| | View in PubMed
- Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer.| | View in PubMed
- Divergent management strategies for typical versus atypical carcinoid tumors of the thoracic cavity.| | View in PubMed
- The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer.| | View in PubMed
- Aggressive and minimally invasive surgery for pulmonary metastasis of sarcoma.| | View in PubMed
- A novel use of foley catheters to prevent injury to the pelvic viscera during stereotactic radiosurgery for undifferentiated pleomorphic sarcoma of the sacrum.| | View in PubMed
- VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer.| | View in PubMed
- Desmoplastic fibroma of the spine causing severe mediastinal compression and brachial plexus encasement: report of 2 cases.| | View in PubMed
- Non-small cell lung cancer, version 2.2013.| | View in PubMed
- Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology.| | View in PubMed
- Small cell lung cancer.| | View in PubMed
- Non-small cell lung cancer.| | View in PubMed
- Determination of cutpoints for low and high number of symptoms in patients with advanced cancer.| | View in PubMed
- A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.| | View in PubMed
- One size does not fit all lung cancer patients.| | View in PubMed
- Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans.| | View in PubMed
- A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.| | View in PubMed
- Malignant pleural mesothelioma.| | View in PubMed
- Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).| | View in PubMed
- Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer.| | View in PubMed
- Emerging antiangiogenic therapies for non-small-cell lung cancer.| | View in PubMed
- Small cell lung cancer.| | View in PubMed
- Lung cancer stigma, depression, and quality of life among ever and never smokers.| | View in PubMed
- A review of the literature on multiple symptoms, their predictors, and associated outcomes in patients with advanced cancer.| | View in PubMed
- Measuring stigma in people with lung cancer: psychometric testing of the cataldo lung cancer stigma scale.| | View in PubMed
- Thymic malignancies.| | View in PubMed
- Non-small cell lung cancer.| | View in PubMed
- Differences in symptom clusters identified using occurrence rates versus symptom severity ratings in patients at the end of radiation therapy.| | View in PubMed
- A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.| | View in PubMed
- Changes in symptom clusters in patients undergoing radiation therapy.| | View in PubMed
- Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer.| | View in PubMed
- A review of the prevalence and impact of multiple symptoms in oncology patients.| | View in PubMed
- Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS).| | View in PubMed
- Non-small cell lung cancer.| | View in PubMed
- Small cell lung cancer.| | View in PubMed
- Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.| | View in PubMed
- Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain.| | View in PubMed
- Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).| | View in PubMed
- Non-small cell lung cancer clinical practice guidelines in oncology.| | View in PubMed
- Small cell lung cancer clinical practice guidelines in oncology.| | View in PubMed
- Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.| | View in PubMed
- Unusual thoracic problems in patients with malignancies: case 3. Carcinoid tumor of the thymus.| | View in PubMed
- Mechanisms of and potential treatment strategies for metastatic disease in non-small cell lung cancer.| | View in PubMed